A neuregulin 1 transmembrane domain mutation causes imbalanced glutamatergic and dopaminergic receptor expression in mice

Neuroscience

Volumn 248, Issue , 2013, Pages 670-680

  Newell, K A ^a,b   Karl, T ^b,c,d,e   Huang, X F ^a,b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^c NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

CB1 receptor; D2 receptor; Mouse; Neuregulin; NMDA receptor; Schizophrenia

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ACETYLCHOLINE; CANNABINOID 1 RECEPTOR; DIZOCILPINE; DOPAMINE RECEPTOR; GLUTAMATE RECEPTOR; GLUTAMATERGIC N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID; NEU DIFFERENTIATION FACTOR; PIRENZEPINE; RACLOPRIDE; UNCLASSIFIED DRUG;

ANATOMICAL VARIATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CENTRAL NERVOUS SYSTEM; CINGULATE GYRUS; CONTROLLED STUDY; GENE; GENE INTERACTION; GENE MUTATION; GENETIC SUSCEPTIBILITY; MALE; MOUSE; NEUREGULIN 1 GENE; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SCHIZOPHRENIA; SENSORY CORTEX; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; THALAMUS; TISSUE DISTRIBUTION;

4-(2-HYDROXYETHYL)-1-PIPERAZINEETHANESULFONIC ACID; ANALYSIS OF VARIANCE; ANOVA; CB1 RECEPTOR; D2 RECEPTOR; DISC1; DISRUPTED IN SCHIZOPHRENIA 1; EDTA; EGF; EPIDERMAL GROWTH FACTOR; ERBB4; ETHYLENEDIAMINE TETRAACETIC ACID; GABA; GAMMA-AMINOBUTYRIC ACID; HEPES; HETEROZYGOUS TRANSMEMBRANE DOMAIN NEUREGULIN 1 MUTANT MOUSE; MANOVA; MOUSE; MULTIVARIATE ANALYSIS OF VARIANCE; N-METHYL-D-ASPARTATE; NEUREGULIN; NEUREGULIN 1; NMDA; NMDA RECEPTOR; NRG1; NRG1(+/-); SCHIZOPHRENIA; V-ERB-A ERYTHROBLASTIC LEUKAEMIA VIRAL ONCOGENE HOMOLOGUE 4; WILD TYPE-LIKE; WT;

ANIMALS; MALE; MICE; MUTATION; NEUREGULIN-1; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, CANNABINOID, CB1; RECEPTORS, DOPAMINE; RECEPTORS, MUSCARINIC; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 84881545937     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.06.037     Document Type: Article

References (67)

1. Bailey K.R., Rustay N.R., Crawley J.N. Behavioral phenotyping of transgenic and knockout mice: practical concerns and potential pitfalls. Institute for Laboratory Animal Research Journal 2006, 47:124-131.
2. Bakker S.C., Hoogendoorn M.L., Selten J.P., Verduijn W., Pearson P.L., Sinke R.J., Kahn R.S. Neuregulin 1: genetic support for schizophrenia subtypes. Mol Psychiatry 2004, 9:1061-1063.
3. Barakat A., Dean B., Scarr E., Evin G. Decreased neuregulin 1 C-terminal fragment in Brodmann's area 6 of patients with schizophrenia. Schizophr Res 2010, 124:200-207.
4. Bernstein H.G., Lendeckel U., Bertram I., Bukowska A., Kanakis D., Dobrowolny H., Stauch R., Krell D., Mawrin C., Budinger E., Keilhoff G., Bogerts B. Localization of neuregulin-1alpha (heregulin-alpha) and one of its receptors, ErbB-4 tyrosine kinase, in developing and adult human brain. Brain Res Bull 2006, 69:546-559.
5. Bjarnadottir M., Misner D.L., Haverfield-Gross S., Bruun S., Helgason V.G., Stefansson H., Sigmundsson A., Firth D.R., Nielsen B., Stefansdottir R., Novak T.J., Stefansson K., Gurney M.E., Andresson T. Neuregulin 1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/- knock-outs compared with wild-type mice. J Neurosci 2007, 27:4519-4529.
6. Boucher A.A., Arnold J.C., Duffy L., Schofield P.R., Micheau J., Karl T. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. Psychopharmacology 2007, 192:325-336.
7. Boucher A.A., Hunt G.E., Karl T., Micheau J., McGregor I.S., Arnold J.C. Heterozygous neuregulin 1 mice display greater baseline and Delta(9)-tetrahydrocannabinol-induced c-Fos expression. Neuroscience 2007, 149:861-870.
8. Carlsson T., Schindler F.R., Höllerhage M., Depboylu C., Arias-Carrión O., Schnurrbusch S., Rösler T.W., Wozny W., Schwall G.P., Groebe K., Oertel W.H., Brundin P., Schrattenholz A., Höglinger G.U. Systemic administration of neuregulin-1β1 protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neurochem 2011, 117:1066-1074.
9. Chesworth R., Downey L., Killcross S., Lodge W., Karl T. Cognition in female transmembrane domain neuregulin 1 mutant mice. Behav Brain Res 2012, 226:218-223.
10. Chong V.Z., Thompson M., Beltaifa S., Webster M.J., Law A.J., Weickert C.S. Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients. Schizophr Res 2008, 100:270-280.
11. Cohen M., Solowij N., Carr V. Cannabis, cannabinoids and schizophrenia: integration of the evidence. Aust N Z J Psychiatry 2008, 42:357-368.
12. Corfas G., Roy K., Buxbaum J.D. Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat Neurosci 2004, 7:575-580.
13. Crook J.M., Tomaskovic-Crook E., Copolov D.L., Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 2001, 158:918-925.
14. Crowley J.J., Keefe R.S., Perkins D.O., Stroup T.S., Lieberman J.A., Sullivan P.F. The neuregulin 1 promotor polymorphism rs 6994992 is not associated with chronic schizophrenia or neurocognition. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:1298-1300.
15. Dean B., Crook J.M., Opeskin K., Hill C., Keks N., Copolov D.L. The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia [see comment]. Mol Psychiatry 1996, 1:54-58.
16. 3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001, 103:9-15.
17. Dean B., Karl T., Pavey G., Boer S., Duffy L., Scarr E. Increased levels of serotonin 2A receptors and serotonin transporter in the CNS of neuregulin 1 hypomorphic/mutant mice. Schizophr Res 2008, 99:341-349.
18. Deng C., Huang X.F. Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia. J Neurosci Res 2005, 81:883-890.
19. du Bois T.M., Hsu C.W., Li Y., Tan Y.Y., Deng C., Huang X.F. Altered dopamine receptor and dopamine transporter binding and tyrosine hydroxylase mRNA expression following perinatal NMDA receptor blockade. Neurochem Res 2008, 33:1224-1231.
20. Duffy L., Cappas E., Lai D., Boucher A.A., Karl T. Cognition in transmembrane domain neuregulin 1 mutant mice. Neuroscience 2010, 170:800-807.
21. Franklin K.B.J., Paxinos G. The mouse brain in stereotaxic coordinates 1997, Academic Press, Sydney.
22. Geddes A.E., Huang X.F., Newell K.A. Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin 1 and their role in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:896-904.
23. Harrison P.J., Law A.J. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 2006, 60:132-140.
24. Harrison P.J., Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005, 10:40-68.
25. Hashimoto R., Straub R.E., Weickert C.S., Hyde T.M., Kleinman J.E., Weinberger D.R. Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia. Mol Psychiatry 2004, 9:299-307.
26. Kato T., Kasai A., Mizuno M., Fengyi L., Shintani N., Maeda S., Yokoyama M., Ozaki M., Nawa H. Phenotypic characterization of transgenic mice overexpressing neuregulin-1. PLoS One 2010, 5:e14185.
27. Kato T., Abe Y., Sotoyama H., Kakita A., Kominami R., Hirokawa S., Ozaki M., Takahashi H., Nawa H. Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia. Mol Psychiatry 2011, 16:307-320.
28. Karl T., Duffy L., Scimone A., Harvey R.P., Schofield P.R. Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes Brain Behav 2007, 6:677-687.
29. Karl T., Burne T.H.J., Van den Buuse M., Chesworth R. Do transmembrane domain neuregulin 1 mutant mice exhibit a reliable sensorimotor gating deficit?. Behav Brain Res 2011, 223:336-341.
30. Kim J.W., Lee Y.S., Cho E.Y., Jang Y.L., Park D.Y., Choi K.S., Jeun H.O., Cho S.H., Jang S.Y., Hong K.S. Linkage and association of schizophrenia with genetic variations in the locus of neuregulin 1 in Korean population. Am J Med Gen B Neuropsychiatr Genet 2006, 141B:281-286.
31. Knable M.B., Hyde T.M., Herman M.M., Carter J.M., Bigelow L., Kleinman J.E. Quantitative autoradiography of dopamine-D1 receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients. Biol Psychiatry 1994, 36:827-835.
32. 3H]MK-801 binding sites in post-mortem human frontal cortex. Eur J Pharmacol 1989, 162:483-490.
33. Laurie D.J., Bartke I., Schoepfer R., Naujoks K., Seeburg P.H. Regional, developmental and interspecies expression of the four NMDAR2 subunits, examined using monoclonal antibodies. Brain Res 1997, 51:23-32.
34. Law A.J., Kleinman J.E., Weinberger D.R., Weickert C.S. Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Hum Mol Genet 2007, 16:129-141.
35. Law A.J., Lipska B.K., Weickert C.S., Hyde T.M., Straub R.E., Hashimoto R., Harrison P.J., Kleinman J.E., Weinberger D.R. Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease. Proc Natl Acad Sci U S A 2006, 103:6747-6752.
36. Long L., Chesworth R., Arnold J.C., Karl T. A follow-up study: acute behavioural effects of δ9-THC in female heterozygous neuregulin 1 transmembrane domain mutant mice. Psychopharmacology 2010, 211:277-289.
37. Long L.E., Chesworth R., Huang X.F., Wong A., Spiro A., McGregor I.S., Arnold J.C., Karl T. Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice. PLos One 2012, 7:e34129.
38. Long L., Frank E., Huang X., Karl T., Shannon Weickert C. Transmembrane domain Nrg1 mutation alters Nrg1 and interneuron marker expression. Schizophrenia Bulletin 2013, 39(Suppl.1):S122.
39. Marballi K., Cruz D., Thompson P., Walss-Bass C. Differential neuregulin 1 cleavage in the prefrontal cortex and hippocampus in schizophrenia and bipolar disorder: preliminary findings. PLoS One 2012, 7:e36431.
40. Mei L., Xiong W.C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 2008, 9:437-452.
41. Moon E., Rollins B., Mesen A., Sequeira A., Myers R.M., Akil H., Watson S.J., Barchas J., Jones E.G., Schatzberg A., Bunney W.E., DeLisi L.E., Byerley W., Vawter M.P. Lack of association to a NRG1 missense polymorphism in schizophrenia or bipolar disorder in a Costa Rican population. Schizophr Res 2011, 131:52-57.
42. Newell K.A., Deng C., Huang X.F. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res 2006, 172:556-560.
43. Newell K.A., Zavitsanou K., Huang X.F. Ionotropic glutamate receptor binding in the posterior cingulate cortex in schizophrenia patients. Neuroreport 2005, 16:1363-1367.
44. Newell K.A., Zavitsanou K., Jew S.K., Huang X.F. Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:225-233.
45. Newell K.A., Zavitsanou K., Huang X.F. Opposing short- and long-term effects on muscarinic M1/4 receptor binding following chronic phencyclidine treatment. J Neurosci Res 2007, 85:1358-1363.
46. Newell K.A., Zavitsanou K., Huang X.F. Short and long term changes in NMDA receptor binding in mouse brain following chronic phencyclidine treatment. J Neural Transm 2007, 114:995-1001.
47. O'Tuathaigh C.M., Babovic D., O'Sullivan G.J., Clifford J.J., Tighe O., Croke D.T., Harvey R., Waddington J.L. Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1. Neuroscience 2007, 147:18-27.
48. O'Tuathaigh C.M., Harte M., O'Leary C., O'Sullivan G.J., Blau C., Lai D., Harvey R.P., Tighe O., Fagan A.J., Kerskens C., Reynolds G.P., Waddington J.L. Schizophrenia-related endophenotypes in heterozygous neuregulin-1 'knockout' mice. Eur J Neurosci 2010, 31:349-358.
49. Ozaki M., Sasner M., Yano R., Lu H.S., Buonanno A. Neuregulin-β induces expression of an NMDA-receptor subunit. Nature 1997, 390:691-694.
50. Paoletti P., Neyton J. NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol 2007, 7:39-47.
51. Sanders A.R., Duan J., Levinson D.F., Shi J., He D., Hou C., Burrell G.J., Rice J.P., Nertney D.A., Olincy A., Rozic P., Vinogradov S., Buccola N.G., Mowry B.J., Freedman R., Amin F., Black D.W., Silverman J.M., Byerley W.F., Crowe R.R., Cloninger C.R., Martinez M., Gejman P.V. No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics. Am J Psychiatry 2008, 165:497-506.
52. Scarr E., Pavey G., Sundram S., MacKinnon A., Dean B. Decreased hippocampal NMDA, but not kainite or AMPA receptors in bipolar disorder. Bipolar Disord 2003, 5:257-264.
53. Scarr E., Beneyto M., Meador-Woodruff J.H., Dean B. Cortical glutamatergic markers in schizophrenia. Neuropsychopharmacology 2005, 30:1521-1531.
54. Schmitt A., Koschel J., Zink M., Bauer M., Sommer C., Frank J., Treutlein J., Schulze T., Schneider-Axmann T., Parlapani E., Rietschel M., Falkai P., Henn F.A. Gene expression of NMDA receptor subunits in the cerebellum of elderly patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 2010, 260:101-111.
55. South T., Huang X.F. High-fat diet exposure increases dopamine D2 receptor and decreases dopamine transporter receptor binding density in the nucleus accumbens and caudate putamen of mice. Neurochem Res 2008, 33:598-605.
56. South T., Huang X.F. Temporal and site-specific alterations in CB1 receptor binding in high fat diet-induced obesity in C57Bl/6 mice. J Neuroendocrinol 2008, 20:1288-1294.
57. Spencer J.R., Darbyshire K.M.E., Boucher A.A., Arnold J.C. Adolescent neuregulin 1 heterozygous mice display enhanced behavioural sensitivity to methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry 2012, 39:376-381.
58. Stefansson H., Sarginson J., Kong A., Yates P., Steinthorsdottir V., Gudfinnsson E., Gunnarsdottir S., Walker N., Petursson H., Crombie C., Ingason A., Gulcher J.R., Stefansson K., St Clair D. Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet 2003, 72:83-87.
59. Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., Brynjolfsson J., Gunnarsdottir S., Ivarsson O., Chou T.T., Hjaltason O., Birgisdottir B., Jonsson H., Gudnadottir V.G., Gudmundsdottir E., Bjornsson A., Ingvarsson B., Ingason A., Sigfusson S., Hardardottir H., Harvey R.P., Lai D., Zhou M., Brunner D., Mutel V., Gonzalo A., Lemke G., Sainz J., Johannesson G., Andresson T., Gudbjartsson D., Manolescu A., Frigge M.L., Gurney M.E., Kong A., Gulcher J.R., Petursson H., Stefansson K. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002, 71:877-892.
60. Uchida S., Kato Y., Hirano K., Kagawa Y., Yamada S. Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci 2007, 80:1635-1640.
61. Van den Buuse M., Wischoff L., Lee R.X., Martin S., Karl T. Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation. Int J Neuropsychopharmacol 2009, 12:1383-1393.
62. Walss-Bass C., Liu W., Lew D.F., Villegas R., Montero P., Dassori A., Leach R.J., Almasy L., Escamilla M., Raventos H. A novel missense mutation in the transmembrane domain of neuregulin 1 is associated with schizophrenia. Biol Psychiatry 2006, 60:548-553.
63. Wenzel A., Fritschy J.M., Mohler H., Benke D. NMDA receptor heterogeneity during postnatal development of the rat brain: differential expression of the NR2A, NR2B, and NR2C subunit proteins. J Neurochem 1997, 68:469-478.
64. Williams N.M., Preece A., Spurlock G., Norton N., Williams H.J., Zammit S., O'Donovan M.C., Owen M.J. Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia [see comment]. Mol Psychiatry 2003, 8:485-487.
65. Yurek D.M., Zhang L., Fletcher-Turner A., Seroogy K.B. Supranigral injection of neuregulin 1-[beta] induces striatal dopamine overflow. Brain Res 2004, 1028:116-119.
66. Zavitsanou K., Katsifis A., Mattner F., Huang X.F. Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 2004, 29:619-625.
67. Zavitsanou K., Ward P.B., Huang X.F. Selective alterations in ionotropic glutamate receptors in the anterior cingulate cortex in schizophrenia. Neuropsychopharmacology 2002, 27:826-833.